Fluoroquinolone exposure prior to tuberculosis diagnosis is associated with an increased risk of death

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 9, 2012, Pages 1162-1167

  Van Der Heijden, Yuri F ^a   Maruri, F ^a   Blackman, A ^a   Holt, E ^a,b   Warkentin, J V ^b   Shepherd, B E ^a   Sterling, T R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TENNESSEE DEPARTMENT OF HEALTH   (United States)

Author keywords

Drug resistance; Drug susceptible TB; Mortality

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGE; AGED; ARTICLE; CAUSE OF DEATH; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RATE; INFECTION RISK; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SPUTUM SMEAR;

ADULT; AGE FACTORS; AGED; ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; COINFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; FLUOROQUINOLONES; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; ODDS RATIO; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SPUTUM; TENNESSEE; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84865226888     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0046     Document Type: Article

References (22)

1. World Health Organization. Global tuberculosis control: WHO report 2011. WHO/HTM/TB/2011.16. Geneva, Switzerland: WHO, 2011. http://www.who.int/tb/ publications/global-report/2011/gtbr11-full.pdf Accessed May 2012.
2. Pablos-Mendez A, Sterling T R, Frieden T R. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA 1996; 276: 1223-1228. (Pubitemid 26337704)
3. Marks S M, Magee E, Robison V. Patients diagnosed with tuberculosis at death or who died during therapy: association with the human immunodeficiency virus. Int J Tuberc Lung Dis 2011; 15: 465-470.
4. Nguyen L T, Hamilton C D, Xia Q, Stout J E. Mortality before or during treatment among tuberculosis patients in North Carolina, 1993-2003. Int J Tuberc Lung Dis 2011; 15: 257-262.
5. Fielder J F, Chaulk C P, Dalvi M, Gachuhi R, Comstock G W, Sterling T R. A high tuberculosis case-fatality rate in a setting of effective tuberculosis control: implications for acceptable treatment success rates. Int J Tuberc Lung Dis 2002; 6: 1114-1117. (Pubitemid 36054967)
6. Sterling T R, Zhao Z, Khan A, et al. Mortality in a large tuberculosis treatment trial: modifiable and non-modifiable risk factors. Int J Tuberc Lung Dis 2006; 10: 542-549. (Pubitemid 43667643)
7. Ginsburg A S, Grosset J H, Bishai W R. Fluoroquinolones, tuberculosis and resistance. Lancet Infect Dis 2003; 3: 432-442.
8. Hu Y, Coates A R, Mitchison D A. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47: 653-657. (Pubitemid 36158096)
9. Gaba P D, Haley C, Griffin M R, et al. Increasing out-patient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease. Arch Intern Med 2007; 167: 2317-2322. (Pubitemid 350179526)
10. Long R, Chong H, Hoeppner V, et al. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Clin Infect Dis 2009; 48: 1354-1360.
11. Ginsburg A S, Hooper N, Parrish N, et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis 2003; 37: 1448-1452. (Pubitemid 37494671)
12. Devasia R A, Blackman A, Gebretsadik T, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 2009; 180: 365-370.
13. Yoon Y S, Lee H J, Yoon H I, et al. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. Int J Tuberc Lung Dis 2005; 9: 1215-1219. (Pubitemid 41735599)
14. Wang J Y, Hsueh P R, Jan I S, et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006; 61: 903-908.
15. Jeon C Y, Calver A D, Victor T C, Warren R M, Shin S S, Murray M B. Use of fluoroquinolone antibiotics leads to tuberculosis treatment delay in a South African gold mining community. Int J Tuberc Lung Dis 2011; 15: 77-83.
16. Dooley K E, Golub J, Goes F S, Merz W G, Sterling T R. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002; 34: 1607-1612. (Pubitemid 34615446)
17. Golub J E, Bur S, Cronin W A, et al. Impact of empiric antibiotics and chest radiograph on delays in the diagnosis of tuberculosis. Int J Tuberc Lung Dis 2005; 9: 392-397. (Pubitemid 40524029)
18. Català L, Orcau A, García de Olalla P, Millet J-P, Rodríguez-Mondragón A, Caylà J A. Survival of a large cohort of HIV-infected tuberculosis patients in the era of highly active antiretroviral treatment. Int J Tuberc Lung Dis 2011; 15: 263-269.
19. Oursler K K, Moore R D, Bishai W R, Harrington S M, Pope D S, Chaisson R E. Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. Clin Infect Dis 2002; 34: 752-759. (Pubitemid 34194844)
20. US Census Bureau. 2009 Regional tuberculosis case and rate table with population estimates. Washington DC, USA: US Census Bureau, 2009. http://health.state.tn.us/Downloads/TB-2009-bycounty.pdf Accessed May 2012.
21. Wang M, FitzGerald J M, Richardson K, et al. Is the delay in diagnosis of pulmonary tuberculosis related to exposure to fluoroquinolones or any antibiotic? Int J Tuberc Lung Dis 2011; 15: 1062-1068.
22. Chen T C, Lu P L, Lin C Y, Lin W R, Chen Y H. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int J Infect Dis 2011; 15: e211-216.